Alchemab specializes in antibody mining. First, they identify exceptionally immunologically resilient individuals. Then they sequence B cells from these individuals and identify antibodies with similar properties using computational drug discovery methods. Alchemab has discovered four drug candidates. At present two of these candidates target solid cancer tumors, one targets Covid, and one targets a molecule involved in the development of Alzheimer’s disease. One of Alchemab’s cancer targeting antibodies is currently in preclinical testing. Dr. Young Kwon is the CEO and Dr. Jane Osbourn is the CSO. Dr. Rachel Bashford-Rogers and Dr. Ben Larman are the scientific founders of Alchemab.